Patients undergoing laser treatment were 33% more likely to experience pain and 50% more likely to require postoperative pain medication than patients who received the ClosureFast treatment.
The multi-center prospective study included ClosureFAST patients from 13 centers in the US and Europe. Among 324 patients (395 limbs) in the study, 142 limbs had one-year followup data, with a vein occlusion rate of 96.2% at one year using Kaplan-Meier analysis.
The VNUS ClosureFAST catheter is an endovenous radiofrequency (RF) ablation catheter designed to heat and close diseased saphenous veins that cause varicose veins.
Alan Dietzek, chief of Vascular Surgery at Danbury Hospital, Danbury, said: “VNUS ClosureFast is a major step forward in the management of venous disease. Results so far have exceeded expectations, especially the excellent treatment efficacy combined with very mild postoperative patient recovery. Furthermore, with ClosureFast it is now possible to perform endovenous ablation of the saphenous vein faster than with any other device or mode of treatment available.”